Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Isla McClelland

Adult Congenital Heart Disease Dublin, OH Medical Doctor

NPI 1588907810 CMS profile 1345761

6700 University Blvd, Dublin, OH 43016

Open in the dashboard

General payments

$328

12 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Isla McClelland of Dublin, OH is reported in the CMS Open Payments database as having received $328 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $12 1
2021 General $27 2
2020 General $58 3
2019 General $231 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Isla McClelland
  • Adult Congenital Heart Disease median
  • Middle half of Adult Congenital Heart Disease
  • National median

In program year 2025, general payments to Isla McClelland were reported at $0. Among 56 Adult Congenital Heart Disease profiles paid that year, the median was $272 and the middle half received between $51 and $642.

Show as a table
Year Isla McClelland Adult Congenital Heart Disease median Middle half National median
2019 $231 $202 $71–$498 $163
2020 $58 $127 $28–$236 $114
2021 $27 $138 $34–$310 $132
2022 $12 $275 $125–$1,572 $149
2023 $0 $215 $58–$1,454 $160
2024 $0 $273 $84–$801 $164
2025 $0 $272 $51–$642 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Medtronic Vascular, Inc. $174 3 payments
  2. Pfizer Inc. $82 4 payments
  3. Novartis Pharmaceuticals Corporation $39 3 payments
  4. Abbott Laboratories $20 1 payment
  5. Amgen Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $328 12 payments
Products named General payments · program years 2019–2022
  1. ELIQUIS $82 4 payments
  2. VYNDAQEL $62 3 payments
  3. ENTRESTO $39 3 payments
  4. CardioMEMS HF System $20 1 payment
  5. Repatha $14 1 payment
  6. Corlanor $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

294

Median for Cardiology: 2,533

Drug cost

$68,782

Median for Cardiology: $485,213

Branded share of claims

14.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 31 $46,594
Entresto Sacubitril/Valsartan Brand 11 $20,150
Atorvastatin Calcium Generic 58 $552
Metoprolol Succinate Generic 40 $375
Amiodarone Hcl Generic 17 $309
Rosuvastatin Calcium Generic 46 $261
Losartan Potassium Generic 30 $206
Carvedilol Generic 29 $153
Lisinopril Generic 15 $101
Furosemide Generic 17 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$50,303

Medicare's payments for the services billed

Medicare patients

738

Average age 72

Services billed

1,108

364 women, 374 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 52%
Atrial fibrillation 50%
Heart failure 43%
Chronic kidney disease 39%
Diabetes 38%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Congenital Heart Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record